An observational study in SARS-CoV-2 Infection, sponsored by NYU Langone Health. Active, not recruiting at 65 sites in United States. Open to participants aged Up to 25 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by NYU Langone Health · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in COVID-19 by NYU Langone Health — 1 open to participants now, 4 under way, none of them phase 3. COVID-19 · NYU Langone Health.
Among the 16 studies in COVID-19 by NYU Langone Health, this one is one of 3 that started in 2022, is one of 7 observational ones, and was the 12th registered.
7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.
Browse COVID-19 studies →1 of the 16 studies in COVID-19 by NYU Langone Health is open now, in 1 country. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.
This study: Up to 25 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2020; this study’s year is marked. 3 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 15,028 is above the median of 268 across 3,209 observational studies indexed under COVID-19.
Median enrollment 87 across the 9 interventional studies, 920 across the 7 observational. Of the 11 that completed or were terminated, 8 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
NYU Langone Health is the lead sponsor of 1,431 studies on the registry; 258 are open to participants now.
Of its 235 completed or terminated interventional studies of FDA-regulated products, 197 (84%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 16 studies in COVID-19 by NYU Langone Health, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a combined retrospective and prospective, longitudinal, observational meta-cohort of individuals age 0-25 years who will enter the cohort with and without SARS-CoV-2 infection at varying stages before and after infection. Individuals with and without SARS-CoV-2 infection and with or without PASC symptoms will be followed to identify risk factors and occurrence of PASC. This study will be conducted in the United States and participants will be recruited through inpatient, outpatient, and community-based settings. Study data including age, demographics, social determinants of health, medical history, vaccination history, details of acute SARS-CoV-2 infection, overall health and physical function, and PASC symptoms will be reported by participants or collected from the electronic health record using a case report form at specified intervals. Biologic specimens will be collected at specified intervals, with some tests performed in local clinical laboratories and others performed by centralized research centers or banked in the Biospecimen Repository. Advanced clinical examinations and radiologic examinations will be performed at local study sites with cross-site standardization.
Ambidirectional longitudinal meta-cohort study (combined retrospective and prospective) with nested case-control studies.
Infected: Individuals less than 25 years of age meeting WHO criteria for suspected, probable or confirmed SARS-CoV-2 infection on or after March 1, 2020; or those born to a mother meeting these criteria during pregnancy.
Uninfected: Individuals less than 25 years of age who have never met any of the WHO criteria for suspected, probable or confirmed SARS-CoV-2 infection.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Infected Cohort:
Patients will be eligible for inclusion according to the following criteria:
Children/Young Adults with Suspected SARS-Cov-2 Infection
Children/young adults who meet these clinical criteria:
At least one of these clinical criteria:
AND at least one of these epidemiological criteria:
A patient with history of severe acute respiratory illness (SARI):
- SARI: acute respiratory infection with history of fever or measured fever of ≥ 38 C°; and cough; with onset within the last 10 days; and requires hospitalization
Children/Young Adults with Probable SARS-Cov-2 Infection
Children/Young Adults with Confirmed SARS-Cov-2 Infection
Children/Young Adults with Asymptomatic SARS-CoV-2 Infection
Non-Infected Cohort
A person who meets the following criteria will qualify for enrollment as a non-infected control subject:
Children (≤3 years of age) born in and out of the context of maternal SARS-CoV-2 infection during pregnancy.
Children with MIS-C
Children/young adults with SARS-CoV-2 infection who have history of MIS-C meeting the CDC definition:
Positive for current or recent SARS-CoV-2 infection by RT-PCR, serology, or antigen test; or exposure to a suspected or confirmed COVID-19 case within the 4 weeks prior to the onset of symptoms.
Children/Young Adults with Post-Vaccine Myocarditis
Children and young adults ages 3-25 years with presence of ≥1 new or worsening of the following clinical symptoms:
OR, children aged 3-12 years might instead have ≥2 of the following symptoms:
lethargy AND
≥1 new finding of:
Entry criteria are adapted from the CDC definition based on the assumptions that COVID-19 vaccines will be available in the future to children \<5 years of age.
Primary Caregiver Entry Criteria
Biological Parent Entry Criteria
- If the primary caregiver is a biological parent of the child or young adult who is participating in the study, the other biological parent may be enrolled to provide a home sample of saliva for DNA analysis.
Exclusion Criteria
An individual who meets any of the following criteria will be excluded from participation in this study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
SARS-CoV-2 infected children and young adults with and without current or prior PASC-like symptoms, including infected individuals with history of multisystem inflammatory syndrome in children (MIS-C), and infants born in the context of maternal SARS-CoV-2 infection during pregnancy
SARS-CoV-2 uninfected children and infants born to uninfected mothers
Newly SARS-CoV-2 infected individuals (≤4 weeks since onset of symptoms or positive laboratory testing)
Contemporaneous SARS-CoV-2 uninfected individuals selected from the same population as newly SARS-CoV-2 infected individuals
Post-acute infected individuals (\>4 weeks after initial symptoms or positive laboratory testing) in the extant, clinical and de novo cohorts, including infants born in the context of maternal SARS-CoV-2 infection during pregnancy, will be enrolled 1-24 months after initial SARS-CoV-2 infection.
Uninfected individuals will be derived from a similar population with respect to age, sex, race and ethnicity, geographic origin, sociodemographics, and time of enrollment as the infected individuals.
Individuals with history of myocarditis after receiving COVID-19 vaccine.
The primary caregiver of the child or young adult may optionally participate in the study.
If the primary caregiver is a biological parent, the other biological parent may optionally participate in the study
Caregiver SARS-CoV-2 Infection Status
Initial SARS-CoV-2 infection is reported via remote patient report (electronic, paper or telephone assessments) and EHR. Infection categories include: SARS CoV 2 PCR result, SARS CoV 2 antigen result, SARS CoV 2 antibody result, SARS CoV 2 sequencing performed, diagnosed by a doctor based on symptoms, suspected by participant but not diagnosed by a doctor.
Time frame: Baseline
Child SARS-CoV-2 Infection Status
Initial SARS-CoV-2 infection is reported via remote patient report (electronic, paper or telephone assessments) and EHR. Infection categories include: SARS CoV 2 PCR result, SARS CoV 2 antigen result, SARS CoV 2 antibody result, SARS CoV 2 sequencing performed, diagnosed by a doctor based on symptoms, suspected by participant but not diagnosed by a doctor.
Time frame: Baseline
Caregiver Severity of SARS-CoV-2 Infection
Severity levels are reported via remote patient report (electronic, paper or telephone assessments) and EHR. NIH severity levels include: asymptomatic or presymptomatic, mild illness, moderate illness, severe illness, and critical illness.
Time frame: Baseline
Child Severity of SARS-CoV-2 Infection
Severity levels are reported via remote patient report (electronic, paper or telephone assessments) and EHR. NIH severity levels include: asymptomatic or presymptomatic, mild illness, moderate illness, severe illness, and critical illness.
Time frame: Baseline
Caregiver Previous In-Hospital SARS-CoV-2 Treatment Record
Treatments will be reported via remote patient report (electronic, paper, or telephone assessment) and EHR -- Treated with corticosteroids , Treated with hydroxychloroquine, Treated with lopinavir, ritonavir, other antiviral, Treated with monoclonal antibody, Treated with therapeutic anticoagulation, Treated with antibiotics.
Time frame: Baseline
Child Previous In-Hospital SARS-CoV-2 Treatment Record
Treatments will be reported via remote patient report (electronic, paper, or telephone assessment) and EHR -- Treated with corticosteroids , Treated with hydroxychloroquine, Treated with lopinavir, ritonavir, other antiviral, Treated with monoclonal antibody, Treated with therapeutic anticoagulation, Treated with antibiotics.
Time frame: Baseline
Caregiver Symptoms
Symptoms will be reported via remote patient report, in-person patient report, or EHR
Time frame: Baseline, up to Month 48
Child Symptoms
Symptoms will be reported via remote patient report, in-person patient report, or EHR -- symptoms include: Nasal Congestion, Trouble breathing, Pain when breathing, Chest pain, Palpitations/heart racing, Dizziness/lightheadedness, Fainting, Change in hearing/ringing in ears, Blurred vision, Change in smell, Change in taste, Problems with teeth or gums, Tremors/shakiness, Feeling off-balance or unsteady, Feeling tingling or "pins and needles", Seizures/fits, Muscle weakness, Difficulty sleeping, Excessive sleepiness, Fatigue/Low energy, Feeling exhausted after walking, Poor appetite, Stomach pains/cramps, Nausea, Vomiting, Diarrhea, Constipation, Problems with urination, Skin rash, Problems with memory, Problems with concentration, Speech difficulty, Anxiety, Depression, Body pain, Headache, Problems swallowing or chewing, Change in menstruation
Time frame: Baseline, up to Month 48
Caregiver SARS-CoV-2 Vaccination Status
Vaccination in status will be reported via remote patient report, in-person patient report, or EHR.
Time frame: Baseline, up to Month 48
Change in Child SARS-CoV-2 Vaccination Status
Vaccination in status will be reported via remote patient report, in-person patient report, or EHR.
Time frame: Week 8, up to Month 48
Change in Caregiver SARS-CoV-2 Treatment Record
Treatments will be reported via remote patient report, in-person patient report, or EHR -- Treated with corticosteroids, Treated with hydroxychloroquine, Treated with lopinavir, ritonavir, other antiviral, Treated with monoclonal antibody, Treated with therapeutic anticoagulation, Treated with antibiotics.
Time frame: Month 12, up to Month 48
Change in Child SARS-CoV-2 Treatment Record
Treatments will be reported via remote patient report, in-person patient report, or EHR -- Treated with corticosteroids, Treated with hydroxychloroquine, Treated with lopinavir, ritonavir, other antiviral, Treated with monoclonal antibody, Treated with therapeutic anticoagulation, Treated with antibiotics.
Time frame: Week 8, up to Month 48
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — All of the individual participant data collected during the trial, after deidentification will be shared upon reasonable request.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: Data will become available beginning 9 months with no end date.
Access criteria: The investigator who proposed to use the data will have access to the data upon reasonable request. Requests should be directed to RECOVER_CSC@NYULangone.org To gain access, data requestors will need to sign a data access agreement.
Started Mar 2022 (actual). Primary completion is estimated for Dec 2028, 81 months after the start.
Of 1,640 non-industry observational studies under COVID-19, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 30. This study's planned 81 months is above that.
Counting every sponsor, half of 1,774 studies reached it within 13 months; a quarter within 5 and three quarters within 29.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion Apr 2027 → Dec 2028 and completion May 2027 → Sep 2029.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.